Ignite Creation Date:
2024-05-06 @ 7:40 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06090630
Status:
COMPLETED
Last Update Posted:
2024-04-17
First Post:
2023-10-13
Brief Title:
MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Study Overview
Official Title:
Non-Uniformly Sampled MR Correlated Spectroscopic Imaging in Breast Cancer and Nonlinear Reconstruction
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial studies how well an imaging technique called magnetic resonance MR spectroscopic imaging works in identifying breast cancer in women with benign or suspicious areas in the breast Magnetic resonance imaging MRI is a diagnostic tool used to investigate the location of tumors in different organs Since radiological pictures do not have sufficient information for tumor grades invasive procedure such as biopsy is performed on patients with breast cancers for diagnosis Breast tissue contains water fat and chemicals known as metabolites MR spectroscopic imaging may help to characterize the various breast metabolite steady state levels and identify the differences between necrosis and tumor recurrence which is difficult using radiological procedures such as MRI
Detailed Description:
PRIMARY OBJECTIVES
I Non-uniform undersampling schemes NUS will be combined with 5-dimensional 5D echo-planar imaging based correlated spectroscopic imaging EP-COSI sequence
II Group sparsity GS-based compressed-sensing CS reconstruction schemes will be developed for accelerated acquisition and optimized to reconstruct the NUS EP-COSI data with better reliability
III Alterations in metabolite and lipid levels will be correlated with apparent diffusion coefficient ADC changes in breast cancer patients compared to healthy women which will improve the diagnostic accuracy
OUTLINE
Participants undergo diffusion weighted imaging DWI-MRI over 15 minutes and MR spectroscopic imaging over 45 minutes
After completion of study participants are followed up for 6 months
I Non-uniform undersampling schemes NUS will be combined with 5-dimensional 5D echo-planar imaging based correlated spectroscopic imaging EP-COSI sequence
II Group sparsity GS-based compressed-sensing CS reconstruction schemes will be developed for accelerated acquisition and optimized to reconstruct the NUS EP-COSI data with better reliability
III Alterations in metabolite and lipid levels will be correlated with apparent diffusion coefficient ADC changes in breast cancer patients compared to healthy women which will improve the diagnostic accuracy
OUTLINE
Participants undergo diffusion weighted imaging DWI-MRI over 15 minutes and MR spectroscopic imaging over 45 minutes
After completion of study participants are followed up for 6 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2019-02258 | REGISTRY | CTRP Clinical Trial Reporting Program | None |